Tubal ectopic molar pregnancy: A case report

Mojgan Hajisafari Tafti, Sajad Zare Garizi, Zare Garizi S, Fatemeh Mazidi, Mazidi F
International journal of reproductive biomedicine · 2024 · vol. 22(5) , pp. 405–410 · doi:10.18502/ijrm.v22i5.16441 · PMID:39091428 · PMC11290199
Case report OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-12 · read from full text ⓘ

This case report describes a 35-year-old woman diagnosed with an invasive hydatidiform mole located in the left fallopian tube, presenting with mild abdominal pain and significantly elevated beta-human chorionic gonadotropin levels. The patient underwent diagnostic curettage followed by a left salpingectomy, with histopathology confirming the presence of molar chorionic villi and intravascular invasion within the ectopic gestational tissue. Postoperative monitoring showed normalized beta-hCG levels over six months, ruling out recurrence or metastasis without the need for chemotherapy. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: Ectopic molar pregnancy (EMP) is a rare form of gestational trophoblastic disease that occurs when a hydatidiform mole implants outside the uterus. CASE PRESENTATION: We describe a 35-yr-old woman with mild abdominal pain, delayed menstruation for 2 months, and high beta-human chorionic gonadotropin levels. Sonography revealed a heterogeneous hyperechoic mass in the left adnexa and fluid in the endometrial cavity, suggestive of a tubal EMP. She underwent endometrial curettage and left salpingectomy. Pathology confirmed the diagnosis of invasive hydatidiform mole/left tubal EMP. The case recovered well and had no complications. CONCLUSION: This case highlights the need for early diagnosis and multidisciplinary treatment of EMP to avoid serious consequences from persistent trophoblastic tumors.
Full text 11,086 characters · extracted from pmc-nxml · 2 sections · click to expand

Section

ZG.S. and M.F. designed the study. HT.M. and M.F. identified and collected the data. ZG.S. and M.F. wrote and reviewed the paper. HT.M. critically reviewed the paper. All authors approved the final version of the paper and took responsibility for its content.

Coi Statement

The authors declare that there is no conflict of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-12T06:16:45.230733+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC